Vortrag
Phase 3, open-label, randomized, controlled study to evaluate immune response, safety and reactogenicity of the RSVPreF3 OA vaccine when coadministered with FLU-QIV-HD vaccine in adults aged ≥65 years
Speaker
Datum:
15.04.2024 ,
Zeit:
11:00
|
Thema: Infektiologie
Details